Corona Remedies reported a 17.28% rise in revenue to ₹1,403.18 crore for FY26. Adjusted PAT increased by 33.45% to ₹199.42 crore, driven by market outperformance and operational efficiencies.

Corona Remedies FY26 Results Show Robust Growth

Revenue from operations for FY26 reached ₹1,403.18 Crores, a 17.28% increase from ₹1,196.42 Crores in FY25. Adjusted Profit After Tax (PAT) grew by 33.45% to ₹199.42 Crores, up from ₹149.43 Crores in the previous fiscal year.

Reader Takeaway: Strong revenue and PAT growth with expanding margins, but brand and geographic concentration persist.

What just happened

Corona Remedies Ltd has announced its financial results for the fiscal year ending March 2026 (FY26). The company reported a significant 17.28% year-on-year growth in its revenue from operations, reaching ₹1,403.18 crore. This growth was driven by a 22.28% increase in Operating EBITDA to ₹293.44 crore and a 33.45% rise in Adjusted PAT to ₹199.42 crore.

Why this matters

These results indicate strong operational performance and market penetration for Corona Remedies. The company has successfully outpaced the overall Indian Pharmaceutical Market (IPM) growth, suggesting effective strategy execution. Improved margins across gross, EBITDA, and PAT levels highlight enhanced profitability and efficiency.

The backstory

Corona Remedies completed its Initial Public Offering (IPO) in December 2025, which saw a subscription of over 101 times. The company also expanded its product portfolio through strategic acquisitions, including seven brands from Bayer Zydus Pharma and Wokadine from Dr. Reddy's Laboratories. These moves aim to bolster its presence in fertility, cardiac, and antiseptic segments.

What changes now

The company is transitioning its Statutory Auditor to M/s. Walker Chandiok & Co LLP from M/s. Deloitte Haskins & Sells LLP. The positive financial performance and strategic acquisitions are expected to strengthen its market position.

Risks to watch

Key concerns include brand concentration, with approximately 76% of domestic sales coming from 32 'Engine Brands'. Geographic concentration is also a factor, as the West Zone accounts for 45.20% of domestic sales.

Peer comparison

Corona Remedies' India business revenue grew by 17.18%, significantly outperforming the IPM growth of 8.59% during the same period.

Context metrics (time-bound)

• Revenue from Operations (FY26): ₹1,403.18 Cr (YoY +17.28%)
• Operating EBITDA (FY26): ₹293.44 Cr (YoY +22.28%)
• Adjusted PAT (FY26): ₹199.42 Cr (YoY +33.45%)
• Covered Market Share: 34.80%
• Overall IPM Rank: 27

What to track next

Investors will be watching the company's progress with its new hormone facility, expected to be commissioned in FY27. Management's efforts to mitigate brand and geographic concentration risks through expansion into South and East India will also be a key focus.